Drug Type Small molecule drug |
Synonyms AGSAVI |
Action antagonists, blockers, inhibitors |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers), Symporters inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H16ClN3O3S |
InChIKeyNDDAHWYSQHTHNT-UHFFFAOYSA-N |
CAS Registry26807-65-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Essential Hypertension | Phase 3 | - | 01 Feb 2021 |